Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Scott L. Friedman Joins Scholar Rock's SAB

This article was originally published in Scrip

Executive Summary

Scholar Rock, a company focused on drugs targeting growth factors in the disease microenvironment, has appointed fibrosis expert Scott L. Friedman to its scientific advisory board (SAB). Friedman is professor of medicine, dean for therapeutic discovery and chief of the division of liver diseases at the Icahn School of Medicine at Mount Sinai Hospital. He has also previously undertaken research into the underlying causes of fibrosis linked to chronic liver disease. Friedman has received various awards for his work including the China Friendship Award in 2014, the International Achievement Prize of the Europe Association for the Study of Liver Diseases in 2012 and the Hans Popper International Liver Research Prize in 2003.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst